ULURU Inc. Announces The Appointment Of Two New Members To The
Board Of Directors
ADDISON, Texas, Jan. 21, 2013 /PRNewswire/ -- ULURU Inc.
(OTCQB: ULUR) announced today the appointment of Helmut Kerschbaumer and Klaus Kuehne as members of the Board of
Directors of ULURU Inc.
As part of the previously announced strategic relationship with
an affiliate of Melmed Holding AG, IPMD GmbH made an equity
investment of $2 million in ULURU
Inc., and was granted the right to appoint two members of the Board
of Directors.
Commenting on the appointment of Helmut
Kerschbaumer and Klaus
Kuehne, Kerry P. Gray,
President and CEO of ULURU Inc., stated, "I am extremely pleased to
have Helmut and Klaus join our Board of Directors. I have worked
closely with them over the past 15 months and have seen the
enormous progress they have made positioning Altrazeal®
for success in the international markets. They have an outstanding
track record as entrepreneurs in development stage medical
companies, taking a company in a period of 5 years from infancy to
a revenue-base of in excess of $30
million, prior to it being acquired. Their experience and
expertise in the development of emerging medical companies will be
a valuable addition to our Board of Directors."
Mr. Kerschbaumer added, "I am very excited to join the Board of
Directors and be involved in determining the strategic direction of
this technology rich company. The products they have developed, and
proposed future product developments, will play a meaningful role
in the improvement of clinical outcomes for patients with
debilitating chronic wounds. I have been very impressed with the
outstanding progress ULURU has made over the past 18 months and
look forward to rapidly accelerating growth."
Mr. Kuehne also added, "We have spent significant time in the
field witnessing the impressive clinical outcomes of
Altrazeal® and discussing with wound experts the market
potential of Altrazeal®. Based on our extensive work, we
believe that both the clinical features and economic benefits of
Altrazeal® are ideally suited to gain a significant
market share of the European and Australasian markets. I look
forward to being involved with management and developing a major
presence in the markets in which ULURU product competes."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company
focused on the development of a portfolio of wound management and
oral care products to provide patients and consumers improved
clinical outcomes through controlled delivery utilizing its
innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal
delivery system. For further information about ULURU Inc.,
please visit our website at www.ULURUInc.com. For further
information about Altrazeal®, please visit
www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended. These statements are subject to numerous
risks and uncertainties, including but not limited to ULURU's lack
of profitability, the need for additional capital to operate its
business, and to risk factors detailed in the Company's Annual
Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us
with the Securities and Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.